Errors phase I | 7 | Norvasc (amlodipine), tablet, 5 mg | Exforge (amlodipine/valsartan), tablet, 5 mg/160 mg |
1 | Pentasa (mesalazine), slow release tablet, 500 mg | Mezavant (mesalazine), tablet, 1200 mg |
1 | Atacand (candesartan), tablet, 8 mg | Atacand Plus (candesartan/hydrochlorothiazide), tablet, 8 mg/12.5 mg |
| Summary phase I: | 9 errors in 99 medication charts (9.1%) 7 made by nurses (11.1% of charts) 2 made by pharmacy technicians (5.6% of charts) |
Errors phase II | 3 | Pentasa (mesalazine), slow release tablet, 500 mg | Mezavant (mesalazine), tablet, 1200 mg |
1 | Norvasc (amlodipine), tablet, 5 mg | Exforge (amlodipine/valsartan), tablet, 5 mg/80 mg |
1 | Valcyte (valganciclovir), tablet, 450 mg | Valtrex (valaciclovir), tablet, 500 mg |
1 | Atacand (candesartan), tablet, 8 mg | Atacand Plus (candesartan/hydrochlorothiazide), tablet, 8 mg/12.5 mg |
1 | Atarax (hydroxyzine), tablet, 25 mg | Atacand (candesartan), tablet, 8 mg |
1 | Atarax (hydroxyzine), tablet, 25 mg | Arava (leflunomide), tablet, 20 mg |
| Summary phase II: | 8 errors in 124 medication charts (6.5%) 4 made by nurses (4.8% of charts) 4 made by pharmacy technicians (9.8% of charts) |